Today, Pacira BioSciences Inc (NASDAQ: PCRX) Takes Center Stage

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

This NASDAQ-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. The current market capitalization of Pacira BioSciences Inc is $1.41B. A total of 1.24 million shares were traded on the day, compared to an average of 598.26K shares.

In the most recent transaction, PACE GARY W sold 90,000 shares of PCRX for 30.60 per share on Mar 08 ’24. After the transaction, the Director now owns 22,127 company shares. In a previous transaction on Mar 07 ’24, PACE GARY W sold 28,257 shares at 30.81 per share. PCRX shares that Director owns now total 112,127.

Among the insiders who sold shares, PACE GARY W disposed of 1,066 shares on Mar 06 ’24 at a per-share price of $29.67. This resulted in the Director holding 140,384 shares of PCRX after the transaction. In another insider transaction, WINSTON ROY sold 509 shares at $34.88 per share on Aug 02 ’23. Company shares held by the Chief Medical Officer now total 52,440.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, PCRX has a high of $42.96 and a low of $25.33.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. PCRX’s latest balance sheet shows that the firm has $656.41M in Cash & Short Term Investments as of fiscal 2021. There were $1.13B in debt and $521.12M in liabilities at the time. Its Book Value Per Share was $19.18, while its Total Shareholder’s Equity was $730.41M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCRX is Buy with a score of 4.70.

Most Popular

Related Posts